N-Methylpiperidine

N-Methylpiperidine

SCHEMBL7712917

CN1CCCCC1.O=C(O)C(Cl)(Cl)Cl

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
LMNA P02545 1/20 0.37
CYP1A2 P05177 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTT P42858 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
CHRM3 P20309 1/20 0.33
CA2 P00918 1/20 0.32
CHKA P35790 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trichloroacetic Acid SCHEMBL7710317 0.98 ALDH1A1 (0.50) ALDH1A1TP53TSHRLMNACYP1A2
Trifluoroacetic Acid SCHEMBL2265017 0.81 ALDH1A1 (0.38) ALDH1A1LMNACYP1A2TDP1MAPK1
N-Methylpiperidine SCHEMBL2071510 0.81 ALDH1A1 (0.38) ALDH1A1LMNACYP1A2TDP1MAPK1
N-Methylpiperidine SCHEMBL2071509 0.81 ALDH1A1 (0.38) ALDH1A1LMNACYP1A2TDP1MAPK1
N-Methylpiperidine SCHEMBL2072770 0.81 ALDH1A1 (0.38) ALDH1A1LMNACYP1A2TDP1MAPK1
N-Methylpiperidine SCHEMBL3849400 0.79 ALDH1A1 (0.47) ALDH1A1LMNACYP1A2TDP1MAPK1
N-Methylpiperidine SCHEMBL996509 0.79 LMNA (0.42) ALDH1A1TSHRLMNACYP1A2TDP1
N-Methylpiperidine SCHEMBL3145445 0.79 CYP1A2 (0.48) ALDH1A1LMNACYP1A2TDP1MAPK1
N-Methylpiperidine SCHEMBL11256632 0.79
Trifluoroacetic Acid SCHEMBL2265475 0.78 HRH4 (0.38) ALDH1A1LMNACYP1A2TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US claimed
US-20250066860-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2025-02-27 US disclosed
CN-111868260-B Methods and materials for assessing and treating cancer 约翰斯霍普金斯大学 2025-02-21 CN disclosed
US-12195803-B2 Methods and materials for assessing and treating cancer THE JOHNS HOPKINS UNIVERSITY (US) 2025-01-14 US disclosed
US-20200377956-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2020-12-03 US disclosed
CN-111868260-A Methods and materials for assessing and treating cancer 约翰斯霍普金斯大学 2020-10-30 CN disclosed
US-20190256924-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2019-08-22 US disclosed
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US disclosed
EP-0958378-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY Rapigene, Inc. (US) 1999-11-24 EP disclosed
EP-0952228-A2 Compositions and methods for enhancing hybridization specificity Rapigene, Inc. (US) 1999-10-27 EP disclosed
WO-1998013527-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY RAPIGENE, INC. (US) 1998-04-02 WO disclosed